Constipation Clinical Trial
Official title:
Randomised Controlled Trial of Efficacy of Resistant Maltodextrins on Reducing Colonic Transit Time
The purpose of this study is to assess the efficacy of resistant maltodextrins, compared to placebo, in reducing the colonic transit time in healthy subjects.
In the last fifty years we have drastically changed our eating habits, in particular our
fibre intake. Our hunter-gatherer ancestors ate more than 100 species of fruit and
vegetables, which contributed between 20 and 30 g of dietary fibre per day. Currently, a
typical citizen of our country reaches 10% of that amount.
Therefore, fibre deficiency alters digestion and metabolism, increasing nutrient absorption
(obesity, increased insulin resistance, hyperlipidaemias), produces altered colonic
metabolism (inflammatory bowel disease), and slows faecal transit (increasing the lumen
pressure with diverticulosis, appendicitis, haemorrhoids and colon cancer. In addition, the
prebiotic effect is important.
Several studies have demonstrated the effectiveness of digestion-resistant maltodextrin in
the treatment of chronic idiopathic constipation. Investigators carried out a single blind
study among young people with constipation who were administered 9.2 grams of resistant
maltodextrins per day or placebo, and found significant changes in defecation frequency and
in faecal volume.
Kimura et al. carried out a clinical trial in women with constipation and a defecation
frequency of less than 3 times per week and administered 5 grams of resistant maltodextrins
per day, demonstrating its effectiveness in significantly increasing the number of
defecations per week, the number of days per week without defecation and the faecal volume.
Additionally, an improvement was found aspects such as colour, stool odour and psychological
feeling after defecation.
Finally, an interesting feature of Resistant maltodextrins is that it normalises the colonic
transit time without causing diarrhoea, whilst increasing the stool volume, moisture and
frequency of defecation.
The purpose of this study is to assess the efficacy of resistant maltodextrins, compared to
placebo, in reducing the colonic transit time in healthy subjects.
For That, 60 subjects will be stratified by gender (30 women: 15 with resistant maltodextrins
and 15 placebo and 30 men: 15 with resistant maltodextrins and 15 placebo).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |